Loading
A phase 3 trial of Doxorubicin, Pegylated liposomal doxorubicin, Topotecan, Gemcitabine, Pembrolizumab and Bevacizumab in ovarian cancer, run by GlaxoSmithKline, now recruiting.
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) is a phase 3 interventional study registered as NCT07286266 by GlaxoSmithKline, with 450 participants planned, started 2026-06-18 and due to reach its primary completion in 2029-12-17. Interventions recorded: Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD), Topotecan, Gemcitabine and Pembrolizumab.
Shares Pegylated liposomal doxorubicin, Topotecan, Platinum-resistant ovarian cancer, Gemcitabine and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Doxorubicin, Gemcitabine, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares GSK, Doxorubicin and the tag pipeline.
Shares GSK, Bevacizumab and the tag pipeline.